Randomized, double-blind study comparing saruplase with streptokinase therapy in acute myocardial infarction: the COMPASS Equivalence Trial. Comparison Trial of Saruplase and Streptokinase (COMASS) Investigators
U Tebbe,
R Michels,
J Adgey,
J Boland,
A Caspi,
B Charbonnier,
J Windeler,
H Barth,
R Groves,
GR Hopkins,
W Fennell,
A Betriu,
M Ruda,
and
J Mlczoch
Klinikum, Lippe-Detmold, Germany.
OBJECTIVES: This study sought to demonstrate the equivalence of saruplase and streptokinase in terms of 30-day mortality. BACKGROUND: The use of thrombolytic agents in the treatment of acute myocardial infarction is well established and has been shown to substantially reduce post-myocardial infarction mortality. METHODS: Three thousand eighty-nine patients with symptoms compatible with those of acute myocardial infarction for < 6 h entered the study at a total of 104 centers and were randomized to receive streptokinase (1.5-MU infusion over 60 min) or saruplase (20-mg bolus and 60-mg infusion over 60 min). In the saruplase group, a bolus of heparin (5,000 IU) was administered before saruplase, and a corresponding blinded double-dummy placebo bolus was administered before streptokinase. All patients received intravenous heparin infusions for > or = 24 h starting 30 min after the end of the thrombolytic infusions; the infusions were titrated to maintain an activated partial thromboplastin time at 1.5 to 2.5 times that of normal. RESULTS: Death of any cause up to 30 days after randomization occurred in 88 (5.7%) of 1,542 patients randomized to receive saruplase and 104 (6.7%) of 1,547 patients randomized to receive streptokinase (odds ratio 0.84, p < 0.01 for equivalence). Hemorrhagic strokes occurred more often in patients receiving saruplase (0.9% vs. 0.3%), whereas thromboembolic strokes were more prevalent in the streptokinase-treated patients (0.5% vs. 1.0%). The rate of bleeding was similar in the two treatment groups (10.4% vs. 10.9%). Hypotension and cardiogenic shock occurred less frequently in the saruplase group. Reinfarction rates were similar. CONCLUSIONS: Saruplase is a clinically safe and effective thrombolytic medication. This profile ranks saruplase favorably among the currently available thrombolytic agents.
This article has been cited by other articles:
|
|
|
|
 
S. Schulman, R. J. Beyth, C. Kearon, and M. N. Levine
Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest,
June 1, 2008;
133(6_suppl):
257S - 298S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. S. Hollenbeak, J. P. Fitzgibbons, M. Rossi, D. L. Morris, and P. Stillman
The Impact of Percutaneous Coronary Interventions on Outcomes for Acute Myocardial Infarction in Pennsylvania
American Journal of Medical Quality,
March 1, 2007;
22(2):
85 - 94.
[Abstract]
[PDF]
|
|
|
|
|
|
|
The Task Force on the Management of Acute Myocardi, F. Van de Werf, D. Ardissino, A. Betriu, D. V. Cokkinos, E. Falk, K. A.A. Fox, D. Julian, M. Lengyel, F.-J. Neumann, et al.
Management of acute myocardial infarction in patients presenting with ST-segment elevation
Eur. Heart J.,
January 1, 2003;
24(1):
28 - 66.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Ronner, R.T. van Domburg, M.J.B.M. van den Brand, P.J. de Feyter, D.P. Foley, W.J. van der Giessen, P.W. Serruys, and M.L. Simoons
Platelet GP IIb/IIIa receptor blockers for failed thrombolysis in acute myocardial infarction, alone or as adjunct to other rescue therapies. A single centre retrospective analysis of 548 consecutive patients with acute myocardial infarction
Eur. Heart J.,
October 1, 2002;
23(19):
1529 - 1537.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Hamel, G. Pacouret, D. Vincentelli, J. F. Forissier, P. Peycher, J. M. Pottier, and B. Charbonnier
Thrombolysis or Heparin Therapy in Massive Pulmonary Embolism With Right Ventricular Dilation : Results From a 128-Patient Monocenter Registry
Chest,
July 1, 2001;
120(1):
120 - 125.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. W. Armstrong and D. Collen
Fibrinolysis for Acute Myocardial Infarction : Current Status and New Horizons for Pharmacological Reperfusion, Part 1
Circulation,
June 12, 2001;
103(23):
2862 - 2866.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E Lesaffre, E Bluhmki, F Wang-Clow, S Berioli, T Danays, N.L Fox, and F Van de Werf
The general concepts of an equivalence trial, applied to ASSENT-2, a large-scale mortality study comparing two fibrinolytic agents in acute myocardial infarction
Eur. Heart J.,
June 1, 2001;
22(11):
898 - 902.
[PDF]
|
|
|
|
|
|
|
E. M. Ohman, R. A. Harrington, C. P. Cannon, G. Agnelli, J. A. Cairns, and J.W. Kennedy
Intravenous Thrombolysis in Acute Myocardial Infarction
Chest,
January 1, 2001;
119
(2009):
253S - 277S.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E Ronner, H.A.M van Kesteren, P Zijnen, E Altmann, P.G Molhoek, L.R van der Wieken, C.A Cuffie-Jackson, K.L Neuhaus, and M.L Simoons
Safety and efficacy of eptifibatide vs placebo in patients receiving thrombolytic therapy with streptokinase for acute myocardial infarction. A phase II dose escalation, randomized, double-blind study
Eur. Heart J.,
September 2, 2000;
21(18):
1530 - 1536.
[Abstract]
[PDF]
|
|
|
|
|
|
|
O. Iqbal, H. Messmore, D. Hoppensteadt, J. Fareed, and W. Wehrmacher
State-of-the-Art Review : Thrombolytic Drugs in Acute Myocardial Infarction
Clinical and Applied Thrombosis/Hemostasis,
January 1, 2000;
6(1):
1 - 13.
[PDF]
|
|
|
|
|
|
|
F.J. Van de Werf
The ideal fibrinolytic: can drug design improve clinical results?
Eur. Heart J.,
October 2, 1999;
20(20):
1452 - 1458.
[PDF]
|
|
|
|
|
|
|
V BERTELE, V TORRI, and S GARATTINI
Inconclusive messages from equivalence trials in thrombolysis
Heart,
June 1, 1999;
81(6):
675 - 676.
[Full Text]
|
|
|
|
|
|
|
N. Danchin, L. Vaur, N. Genes, S. Etienne, M. Angioi, J. Ferrieres, and J.-P. Cambou
Treatment of Acute Myocardial Infarction by Primary Coronary Angioplasty or Intravenous Thrombolysis in the "Real World" : One-Year Results From a Nationwide French Survey
Circulation,
May 25, 1999;
99(20):
2639 - 2644.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Saruplase vs. Streptokinase for AMI
Journal Watch Emergency Medicine,
May 1, 1998;
1998(501):
5 - 5.
[Full Text]
|
|
|
|
|
|
|
H. D. White and F. J. J. Van de Werf
Thrombolysis for Acute Myocardial Infarction
Circulation,
April 28, 1998;
97(16):
1632 - 1646.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Saruplase - A New Thrombolytic
Journal Watch Cardiology,
March 31, 1998;
1998(331):
6 - 6.
[Full Text]
|
|
|
|
